NCT03548675View on ClinicalTrials.gov

Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)

PHASE4CompletedINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

February 2, 2022

Study Completion Date

July 13, 2022

Conditions

Depressive Disorder, Major

Interventions

DRUG

TCA treatment

All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).

Trial Locations (1)

6500 HB

Radboudumc Dept of Psychiatry, Nijmegen

All Listed Sponsors

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Radboud University Medical Center

OTHER

NCT03548675 - Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA) | Biotech Hunter | Biotech Hunter